With the drug compounding industry expanding significantly in recent years, life sciences regulatory & compliance partner Greg Levine and associates Joshua Oyster and Rebecca Williams (all of Washington, D.C.) co-authored a Law360 article published on Sept. 18. The article provides an overview of the current state of the regulatory framework, an analysis of recent case law, and describes the implications for both drug compounders and pharmaceutical manufacturers.
The authors note that while there remain numerous legal issues to be resolved with respect to U.S. Food and Drug Administration regulation of drug compounding, FDA regulatory scrutiny of the compounding practices of outsourcing facilities is unlikely to abate soon.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.